NeuroPace Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

NeuroPace şirketinin toplam hissedar öz sermayesi $9.9M ve toplam borcu $59.0M olup, bu da borç-öz sermaye oranını 597% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $94.4M ve $84.5M dir.

Anahtar bilgiler

597.0%

Borç/özkaynak oranı

US$59.02m

Borç

Faiz karşılama oranı	n/a
Nakit	US$55.54m
Eşitlik	US$9.89m
Toplam yükümlülükler	US$84.50m
Toplam varlıklar	US$94.39m

Son finansal sağlık güncellemeleri

Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?

Apr 12

Recent updates

Why Investors Shouldn't Be Surprised By NeuroPace, Inc.'s (NASDAQ:NPCE) 58% Share Price Surge

Jan 22

NeuroPace, Inc. (NASDAQ:NPCE) Stock Rockets 39% But Many Are Still Ignoring The Company

Apr 17

NeuroPace announces U.S. distribution agreement with DIXI Medical

Aug 11

NeuroPace EPS misses by $32.45, beats on revenue; issues guidance

Jun 03

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: NPCE 'nin kısa vadeli varlıkları ( $80.2M ) kısa vadeli yükümlülüklerini ( $12.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: NPCE şirketinin kısa vadeli varlıkları ( $80.2M ) uzun vadeli yükümlülüklerini ( $71.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: NPCE 'nin net borç/öz sermaye oranı ( 35.2% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: NPCE şirketinin borç/öz sermaye oranının son 5 yılda azalıp azalmadığını belirlemek için yeterli veri yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: NPCE şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: NPCE serbest nakit akışı her yıl % 1.1 oranında tarihsel oranda büyümeye devam ederse 3 yıldan fazla bir süre için yeterli nakit akışına sahip olur

NeuroPace Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?

Recent updates

NeuroPace, Inc. Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy

NeuroPace, Inc. to Report Q3, 2024 Results on Nov 12, 2024

NeuroPace, Inc. Increases Revenue Guidance for 2024

NeuroPace, Inc. (NASDAQ:NPCE) Screens Well But There Might Be A Catch

NeuroPace, Inc. to Report Q2, 2024 Results on Aug 13, 2024

NeuroPace, Inc. Reaffirms Earnings Guidance for the Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2026

NeuroPace, Inc., Annual General Meeting, Jun 07, 2024

NeuroPace, Inc. to Report Q1, 2024 Results on May 08, 2024

Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?

Consensus EPS estimates upgraded to US$1.17 loss

New minor risk - Profitability

NeuroPace, Inc. Provides Earnings Guidance for the Year 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Forecast to breakeven in 2026

NeuroPace: Picking Up The Pace

New minor risk - Share price stability

NeuroPace, Inc. to Report Q4, 2023 Results on Mar 05, 2024

NeuroPace, Inc Announces Resignation of Irina Ridley as Chief Legal Officer and Corporate Secretary

Why Investors Shouldn't Be Surprised By NeuroPace, Inc.'s (NASDAQ:NPCE) 58% Share Price Surge

NeuroPace, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter Ended December 31, 2023

Price target increased by 15% to US$10.50

Forecast to breakeven in 2026

Chief Medical Officer notifies of intention to sell stock

NeuroPace, Inc. Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study

Chief Medical Officer notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Consensus estimates of losses per share improve by 12%

NeuroPace, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Price target increased by 11% to US$7.80

New minor risk - Share price stability

Consensus revenue estimates increase by 14%

NeuroPace, Inc. Revises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

NeuroPace, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Neuropace, Inc. Announces Board Member Changes

NeuroPace, Inc. Revises Earnings Guidance for the Year 2023

Price target increased by 7.7% to US$7.00

NeuroPace, Inc. (NASDAQ:NPCE) Stock Rockets 39% But Many Are Still Ignoring The Company

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased by 11% to US$6.50

NeuroPace, Inc. to Report Q4, 2022 Results on Mar 02, 2023

NeuroPace, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Neuropace, Inc. Announces First Patient with Lennox-Gastaut Syndrome (Lgs) Was Treated in Its Feasibility Investigational Device Exemption (Ide) Study

Price target decreased to US$6.38

Price target decreased to US$6.38

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

NeuroPace, Inc. Revises Earnings Guidance for the Fiscal Year 2022

NeuroPace, Inc. to Report Q3, 2022 Results on Nov 08, 2022

NeuroPace Inc. Announces First Patient Implanted in NAUTILUS Pivotal Study for the Treatment of Idiopathic Generalized Epilepsy

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Neuropace, Inc. Provides Revenue Guidance for 2022

NeuroPace announces U.S. distribution agreement with DIXI Medical

NeuroPace, Inc. to Report Q2, 2022 Results on Aug 11, 2022

NeuroPace, Inc.(NasdaqGM:NPCE) dropped from Russell 2000 Growth Index

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

NeuroPace, Inc. Provides Revenue Guidance for the Year 2022

Neuropace Announces First Patient Treated in Pivotal Study Evaluating the Rns System in Adolescents

Price target decreased to US$11.60

NeuroPace, Inc., Annual General Meeting, Jun 13, 2022

NeuroPace, Inc. to Report Q1, 2022 Results on May 12, 2022

Consensus EPS estimates fall by 75%

Full year 2021 earnings: EPS exceeds analyst expectations

Full year 2021 earnings: EPS exceeds analyst expectations

NeuroPace, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Third quarter 2021 earnings released: US$0.34 loss per share

Less than half of directors are independent

Consensus forecasts updated

NeuroPace, Inc. Reiterates Financial Guidance for the Full Year of 2021

NeuroPace, Inc. Announces the Broad Launch of Its nSight Platform

NeuroPace Awards Five-Year National Institutes of Health Grant Funding of More Than $9 Million to Study RNS System in Patients with Lennox-Gastaut Syndrome

NeuroPace, Inc. Provides Revenue Guidance for the Second Quarter and Full Year of 2021